Lords Mark India acquires 85% holding of Renalyx Health Systems, enters into Renal diagnosis

New Delhi: In a strategic move to strengthen its presence in the medical diagnostics segment, recently listed Mumbai based Lords Mark India (BSE Scrip: 501261), one of India’s fastest-growing diversified business conglomerates has acquired 85% holding in Bengaluru based Renalyx Health Systems.

By March 2026, the acquisition will reach 92% holding. The company will continue to operate as an independent business unit of Lords Mark India.

The acquired company, Renalyx Health Systems is the developer of Renalyx, the world’s first AI powered – Made in India sustained low efficiency dialysis machine (SLED).  The product represents a significant step toward India’s vision of becoming a global MedTech manufacturing hub. RxT 21, is an AI powered and IoT-enabled smart hemodialysis machine, offering remote monitoring, clinical connectivity, real-time data access, supports telenephrology platforms and enhances patient safety and quality of care.

Features of the ISO and CE certified machine includes integration with DNP database for seamless dialysis centre operations and cloud based patient EMR management, one touch operation for streamlined dialysis sessions, SLED mode for intensive care environments, personalised dialysis prescriptions, Kt/V monitoring for dialysis adequacy and clearance validation, single needle dialysis support, Endotoxin removal filter for patient safety, advanced sodium and ultrafiltration profiling.

The dialysis machine will be manufactured in collaboration with Bharat Electronics. Lords Mark recently received its manufacturing license on in September 2025.

Speaking on the acquisition, Sachidanand Upadhyay, Managing Director & CEO of Lords Mark Industries said, “This acquisition reinforces our commitment to driving self-reliance and innovation in India’s Medtech and Diagnostic ecosystem. With Renalyx Health Systems, we’re not only making advanced dialysis more accessible but also putting India on the global MedTech manufacturing map. Our goal is to scale this innovation worldwide, while ensuring that every patient, regardless of geography, has access to safe, efficient and affordable care”

“In April 2025 we shipped our first medtech order of contactless remote patient monitoring and AI based early warning systems worth $1mn to the US. This was more than just an export order for us. The Medtech division of the company today has innovative solutions like TuBerculoScope – an AI enabled Tuberculosis diagnostic device, Aluminium Visual Detection Kit, Extra Cellular Acidity Analyzer, Smart E Clinics, Dozee – a contactless AI enabled ICU monitoring solution besides others,” he further adds.